UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000004678
Receipt number R000005569
Scientific Title Efficacy and safety of DPP-4 inhibitor added to insulin for treatment of type 2 diabetes
Date of disclosure of the study information 2011/01/01
Last modified on 2015/02/10 15:07:02

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Efficacy and safety of DPP-4 inhibitor added to insulin for treatment of type 2 diabetes

Acronym

Efficacy and safety of DPP-4 inhibitor added to insulin for treatment of type 2 diabetes

Scientific Title

Efficacy and safety of DPP-4 inhibitor added to insulin for treatment of type 2 diabetes

Scientific Title:Acronym

Efficacy and safety of DPP-4 inhibitor added to insulin for treatment of type 2 diabetes

Region

Japan


Condition

Condition

Type 2 diabetes

Classification by specialty

Endocrinology and Metabolism

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To investigate the efficacy and the safety of DPP-4 inhibitor in type 2 diabetes mellitus inadequately controlled on intensive insulin therapy

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

HbA1c level after 6 months of treatment (amount and rate of change)

Key secondary outcomes

Amount and rate of change of items and these AUC after test meal(serum glucose, CPR, intact proinsulin, glucagon, FFA, Active GLP-1, Total GIP, TG)
Amount and rate of change after 6 months of treatment(abdominal girth, daily profile of serum glucose by SMBG, Patients QOL questionnaire, Bio-markers for oxidant stress (8-isoprostane, 8-OHdG))
Amount and rate of change after 1, 2, 3, 4, 5, 6 months of treatment(Blood pressure, Body weight, HbA1c, GA, 1,5-AG, CPR, amount and frequency of insulin treatment, rate of hypoglycemic episodes)


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification

YES

Dynamic allocation

YES

Institution consideration

Institution is not considered as adjustment factor.

Blocking

NO

Concealment

Numbered container method


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

DPP-4 inhibitor with intensive insulin therapy

Interventions/Control_2

intensive insulin therapy

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1.Outpatient
2.Patients with intensive insulin therapy
3.HbA1c =>6.5%(JDS).
4.Patients with type 2 diabetes mellitus.
5.No change in therapy with oral antidiabetes agent at least 2 months
6.Age =>20 years
7.Informed consent obtained.

Key exclusion criteria

1.Type 1 diabetes mellitus
2.Impaired renal function [serum-creatinine;
=>1.5mg/dL(male),
=>1.3mg/dL(female) or eGFR<30mL/min]
3.Severe liver dysfunction [AST, ALT=>3 fold above ULN]
4.Patients who are disqualified from the study by investigator for any reasons.

Target sample size

50


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Yoshifumi Saisho

Organization

Keio University , School of Mecidicine

Division name

Department of Internal Medicine

Zip code


Address

35 Shinanomachi, Shinjuku-ku, 160-8582, Tokyo

TEL

03-5363-3797

Email



Public contact

Name of contact person

1st name
Middle name
Last name Yoshifumi Saisho

Organization

Keio University , School of Mecidicine

Division name

Department of Internal Medicine

Zip code


Address

35 Shinanomachi, Shinjuku-ku, 160-8582, Tokyo

TEL

03-5363-3797

Homepage URL


Email

saish@sc.itc.keio.ac.jp


Sponsor or person

Institute

Keio University , School of Mecidicine, Department of Internal Medicine

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

慶應義塾大学病院(東京都)


Other administrative information

Date of disclosure of the study information

2011 Year 01 Month 01 Day


Related information

URL releasing protocol


Publication of results

Published


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2010 Year 09 Month 21 Day

Date of IRB


Anticipated trial start date

2011 Year 01 Month 01 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2010 Year 12 Month 07 Day

Last modified on

2015 Year 02 Month 10 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000005569


Research Plan
Registered date File name
2015/02/10 EDITdata20150109.xlsx

Research case data specifications
Registered date File name

Research case data
Registered date File name
2015/02/10 EDITdata20150109.xlsx